JP2005535298A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535298A5
JP2005535298A5 JP2004505087A JP2004505087A JP2005535298A5 JP 2005535298 A5 JP2005535298 A5 JP 2005535298A5 JP 2004505087 A JP2004505087 A JP 2004505087A JP 2004505087 A JP2004505087 A JP 2004505087A JP 2005535298 A5 JP2005535298 A5 JP 2005535298A5
Authority
JP
Japan
Prior art keywords
glucan
human
locus
antibodies
discloses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004505087A
Other languages
English (en)
Japanese (ja)
Other versions
JP5110767B2 (ja
JP2005535298A (ja
Filing date
Publication date
Priority claimed from GBGB0211118.5A external-priority patent/GB0211118D0/en
Application filed filed Critical
Publication of JP2005535298A publication Critical patent/JP2005535298A/ja
Publication of JP2005535298A5 publication Critical patent/JP2005535298A5/ja
Application granted granted Critical
Publication of JP5110767B2 publication Critical patent/JP5110767B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004505087A 2002-05-15 2003-05-15 グルカンベースのワクチン Expired - Fee Related JP5110767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
GB0211118.5 2002-05-15
PCT/IB2003/002460 WO2003097091A2 (en) 2002-05-15 2003-05-15 Glucan-based vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009294467A Division JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン

Publications (3)

Publication Number Publication Date
JP2005535298A JP2005535298A (ja) 2005-11-24
JP2005535298A5 true JP2005535298A5 (OSRAM) 2012-07-26
JP5110767B2 JP5110767B2 (ja) 2012-12-26

Family

ID=9936711

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004505087A Expired - Fee Related JP5110767B2 (ja) 2002-05-15 2003-05-15 グルカンベースのワクチン
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
JP2012166700A Expired - Fee Related JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
JP2012166700A Expired - Fee Related JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン

Country Status (14)

Country Link
US (4) US20050208079A1 (OSRAM)
EP (2) EP1506009B1 (OSRAM)
JP (3) JP5110767B2 (OSRAM)
AT (2) ATE497781T1 (OSRAM)
AU (1) AU2003241104A1 (OSRAM)
CA (2) CA2830619A1 (OSRAM)
CY (1) CY1108234T1 (OSRAM)
DE (2) DE60336027D1 (OSRAM)
DK (1) DK1506009T3 (OSRAM)
ES (1) ES2306871T3 (OSRAM)
GB (1) GB0211118D0 (OSRAM)
PT (1) PT1506009E (OSRAM)
SI (1) SI1506009T1 (OSRAM)
WO (1) WO2003097091A2 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
DE602005027830D1 (de) * 2004-04-05 2011-06-16 Univ Bordeaux 2 Peptide und peptidmimetika die an cd23 binden
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
JP6082174B2 (ja) * 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
AU2009243094B2 (en) * 2006-11-06 2015-02-12 Massachusetts Institute Of Technology Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
WO2009077854A2 (en) * 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
US9439954B2 (en) 2007-11-26 2016-09-13 Glaxosmithkline Biologicals Sa Conjugated beta-1,3-linked glucans
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
BRPI1008984A2 (pt) * 2009-03-10 2016-07-05 Palmed Teva Ltd novas e distintas variedades de cogumelos basidiomycotas superiores, biomassa de cogumelo, biomassa micelial, extrato de um cogumelo, cultura micelial submersa pura de coprinus comatus, cultura micelial submersa pura de tremella mesentérica, b-glucano de baixo peso molecular solúvel em água 3,4 b-glucano linear insolúvel em água obtiodo a partir de tremella mesentérica, glucuronixilomanano obtido a partir de tremella mesentérica, suplemento alimentar, comida para animais, composição farmacêutica e composição agrícola.
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
KR101440818B1 (ko) * 2010-05-14 2014-11-03 알테크 인코포레이티드 효모 세포벽 성분들 및 이의 검출
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
DK2822947T3 (en) 2012-03-07 2016-09-19 Glaxosmithkline Biologicals Sa ARGINAL SALTS OF A TLR-7 AGONIST
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP3363462A1 (en) * 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
AU2014241492A1 (en) * 2013-03-12 2015-09-17 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
BR112016000585A2 (pt) 2013-07-11 2018-03-20 Novartis Ag modificações quimioenzimáticas sítio-específicas de proteína
CN106170698A (zh) * 2013-12-05 2016-11-30 生物治疗公司 β‑葡聚糖测定方法
CA2973617A1 (en) * 2015-01-26 2016-08-04 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
CA3088832A1 (en) 2018-01-19 2019-07-25 Miltenyi Biotec B.V. & Co. KG Regulatory t cell expressing a chimeric antigen receptor
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
US20250186596A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
CA2066172A1 (en) * 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
EP0471954A3 (en) 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2231770T3 (es) * 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Similar Documents

Publication Publication Date Title
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
JP2006526414A5 (OSRAM)
DE69942911D1 (de) Trägerprotein eines polyepitops
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
ATE390933T1 (de) Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
EP1018344A3 (en) HLA-restricted hepatitis B virus CTL epitopes
NO20050894L (no) Vaksinesammensetninger inneholdende beta-l-6-antigenmatriser
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
He et al. Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model
ATE419007T1 (de) Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen
EP2385059A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2000025722A3 (en) ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
WO2003017032A3 (en) Computer-based methods of designing molecules
EP2057999A3 (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DE60327544D1 (de) Gentechnisch hergestelltes p30-antigen, verbesserter antigen-cocktail und verwendungen davon
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
DE60330004D1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
MXPA04003901A (es) Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
ATE526035T1 (de) Tollwut-impfstoff
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
CN116672443A8 (zh) 七组分抗原非洲猪瘟纳米颗粒疫苗
Heidmeier Recombinant measles viruses: use as bivalent vaccine and modulation of their membrane fusion activity